Ultragenyx (RARE)

The total asset value of Ultragenyx (RARE) stood at $ 1,503 Mln as on 31-Dec-24

The share price of Ultragenyx (RARE) is $35.69 (NASDAQ) as of 17-Apr-2025 16:01 EDT. Ultragenyx (RARE) has given a return of -25.24% in the last 3 years.

Ultragenyx (RARE) has a market capitalisation of $ 3,285 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Ultragenyx (RARE) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ultragenyx (RARE) and enter the required number of quantities and click on buy to purchase the shares of Ultragenyx (RARE).

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California. Address: 60 Leveroni Court, Novato, CA, United States, 94949

The CEO & director of Dr. Emil D. Kakkis M.D., Ph.D.. is Ultragenyx (RARE), and CFO & Sr. VP is Dr. Emil D. Kakkis M.D., Ph.D..

There is no promoter pledging in Ultragenyx (RARE).

Some of the close peers are:

No, TTM profit after tax of Ultragenyx (RARE) was $0 Mln.